ArticleInternational journal of molecular sciences2023
Graphene Oxide/RhPTH(1-34)/Polylactide Composite Nanofibrous Scaffold for Bone Tissue Engineering.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Preparation Methods and Multifunctional Applications of Functionalized Electrospun Nanofibers for Biomedicine.Nanomaterials (Basel, Switzerland) · 2025Review
- Magnesium phosphate functionalized graphene oxide and PLGA composite matrices with enhanced mechanical and osteogenic properties for bone regeneration.Regenerative biomaterials · 2025Article
- Single-layer graphene oxide nanosheets induce proliferation and Osteogenesis of single-cell hBMSCs encapsulated in Alginate Microgels.Scientific reports · 2024Article
- Exploring the Application of Graphene Oxide-Based Nanomaterials in the Repair of Osteoporotic Fractures.Nanomaterials (Basel, Switzerland) · 2024Review
- Nanostructured Coatings Based on Graphene Oxide for the Management of Periprosthetic Infections.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polylactide (PLA) is one of the most promising polymers that has been widely used for the repair of damaged tissues due to its biocompatibility and biodegradability. PLA composites with multiple properties, such as mechanical properties and osteogenesis, have been widely investigated. Herein, PLA/graphene oxide (GO)/parathyroid hormone (rhPTH(1-34)) nanofiber membranes were prepared using a solution electrospinning method. The tensile strength of the PLA/GO/rhPTH(1-34) membranes was 2.64 MPa, nearly 110% higher than that of a pure PLA sample (1.26 MPa). The biocompatibility and osteogenic differentiation test demonstrated that the addition of GO did not markedly affect the biocompatibility of PLA, and the alkaline phosphatase activity of PLA/GO/rhPTH(1-34) membranes was about 2.3-times that of PLA. These results imply that the PLA/GO/rhPTH(1-34) composite membrane may be a candidate material for bone tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.